EUVIMEDEUVIMED entdecken
Crossref

Abstract 9656: Testing for Deferred-Care Harm Around the 30-Day Readmission Threshold for Heart Failure Patients Nationwide

Abstract 9656: Test auf Schaden durch aufgeschobene Versorgung um die 30-Tage-Wiederaufnahmeschwelle bei Herzinsuffizienz-Patient:innen landesweit

James Walker, Raja K Mutharasan, Hongyan Ning, Clyde W Yancy, Donald M Lloyd-Jones

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.9656 ↗

Auf einen Blick

In einer Analyse der NRD 2019 und 2022 zeigte sich an der 30-Tage-Schwelle nach Herzinsuffizienz-Wiederaufnahmen kein Sprung bei Bettentagen, LOS oder Mortalität. Die Werte verliefen eher glatt über die Zeit.

Fragestellung

Sind erste Herzinsuffizienz-Wiederaufnahmen kurz nach Tag 30 mit mehr Bettentagen, längerer Verweildauer oder höherer Mortalität verbunden?

Methode

Analyse der Nationwide Readmissions Database 2019 und 2022; Erwachsene mit Entlassungsdiagnose Herzinsuffizienz und ≥1 Wiederaufnahme innerhalb von 180 Tagen; Vergleich über 14 Zeitfenster und Schwellentests bei Tag 30, 60 und 90.

Ergebnisse

133.871 ungegewichtete Patient:innen. Bettentage sanken von 10,89 (95 %-KI 10,59–11,18) auf 6,57 (6,46–6,68). Bei Tag 30 kein Sprung: Bettentage +0,014 (95 %-KI -0,418 bis 0,446; p=0,95), LOS -0,171 (-0,44 bis 0,098; p=0,21), Wiederaufnahmen +0,022 (-0,015 bis 0,06; p=0,25).

Einschränkungen

Die NRD erfasst keinen Schaden, der in Beobachtung, Notaufnahme oder ambulant auftritt.

Schlussfolgerung der Autor:innen

Es fand sich kein messbarer stationärer Schaden durch aufgeschobene Versorgung an der 30-Tage-Schwelle. LOS und in-hospital mortality zeigten ebenfalls keinen Sprung bei Tag 30.

Kernaussagen

  • Kein discontinuity effect an Tag 30
  • Bettentage nahmen über die Zeit glatt ab
  • NRD erfasst Schäden außerhalb des stationären Settings nicht

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von James Walker und 4 weiteren Autor:innen.

Auf einen BlickAbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Hospital Readmissions Reduction Program (HRRP) penalizes hospitals for excess 30-day heart failure (HF) readmissions. Concern that this may create an incentive to defer borderline readmissions past day 30 using tactics like observation units has been well described. If deferring patient admissions makes patients sicker, hospital bed-day burden, length of stay (LOS), and mortality should rise just past the 30-day threshold. We tested whether first readmissions occurring just after day 30 are associated with an increase in hospital bed-days, LOS, or mortality, consistent with deferred-care harm.

Methods

Using the Nationwide Readmissions Database (NRD) from 2019 and 2022, we included adults with principal discharge diagnosis of HF who were discharged alive. January through June served as our exposure period for index HF admission. Patients were included if they had ≥1 HF readmission within 180 days of index discharge (N=133,871 unweighted). Because the NRD links readmissions only within the same calendar year, follow-up was restricted to 180 days within the index readmission year. Patients were classified into 14 bins by day of first HF readmission. Using survey weights, we compared 6-month HF bed-days, first readmission LOS, LOS ≥7 days, readmission count, and in-hospital mortality across bins, and tested discontinuities at the 30-day threshold (days 26-30 vs 31-35) and placebo cutoffs at days 60 and 90 using Wald tests.

Results

Six-month HF readmission bed-days declined from 10.89 (95% CI 10.59-11.18) in the days 1-5 bin to 6.57 (6.46-6.68) in the days 121-180 bin in a smooth gradient ( Figure ). No discontinuity was detected at day 30. Difference in bed-days (days 31-35 minus days 26-30) was +0.014 (95% CI -0.418 to 0.446; p=0.95), LOS difference was -0.171 (-0.44 to 0.098; p=0.21), and readmission count difference was +0.022 (-0.015 to 0.06; p=0.25). First-readmission (days 26-30 vs 31-35) LOS (6.43 vs 6.26 days), LOS≥7 (32.1% vs 31.5%), and in-hospital mortality (4.14% vs 3.11%) were all stable or slightly declining across the threshold, moving in the direction opposite to the deferred-harm prediction. Placebo tests at days 60 and 90 were null. Difference in bed-days at the day-60 threshold was +0.312 (-0.173 to 0.798; p=0.21) and at the day-90 threshold was -0.058 (-0.545 to 0.429; p=0.82).

Conclusion

Six-month bed-day burden declined smoothly across timing bins, with no discontinuity at the 30-day HRRP threshold. LOS and in-hospital mortality likewise showed no discontinuity at day 30. We found no evidence of measurable inpatient deferred-care harm at the 30-day threshold, though the NRD does not capture harm that may occur in observation, ED, or outpatient settings.

Zitieren

APA

Walker, J., Mutharasan, R. K., Ning, H., Yancy, C. W., & Lloyd-Jones, D. M. (2026). Abstract 9656: Testing for Deferred-Care Harm Around the 30-Day Readmission Threshold for Heart Failure Patients Nationwide. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.9656

Vancouver

Walker J, Mutharasan RK, Ning H, Yancy CW, Lloyd-Jones DM. Abstract 9656: Testing for Deferred-Care Harm Around the 30-Day Readmission Threshold for Heart Failure Patients Nationwide. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.9656

BibTeX
@article{Walker2026,
  author = {Walker, James and Mutharasan, Raja K and Ning, Hongyan and Yancy, Clyde W and Lloyd-Jones, Donald M},
  title = {Abstract 9656: Testing for Deferred-Care Harm Around the 30-Day Readmission Threshold for Heart Failure Patients Nationwide},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.9656}
}
Kostenlos starten →